To evaluate the differential effects of EMT in two different BRAF (V600E) mutant thyroid cancers, PLX4032 was treated to 8505C and BCPAP cells which have each been previously verified as BRAF inhibitor-resistant and -sensitive cell lines, respectively. This evidence concerns the gene BRAF and thyroid gland carcinoma.